What is CJC-1295?

What is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that was modified to resist breakdown and last longer in the body. It was developed by ConjuChem Biotechnologies but never received FDA approval after clinical development was discontinued.

Key Facts

Fact	Detail
FDA Approved	No
Development Status	Discontinued
Administration	Subcutaneous injection
WADA Status	Prohibited

Two Forms Explained

Version	Half-Life	Notes
CJC-1295 with DAC	~8 days	Drug Affinity Complex extends duration
CJC-1295 no DAC	~30 minutes	Also called “Mod GRF 1-29”

The “with DAC” version binds to albumin in the blood, dramatically extending its active time. The version “without DAC” is essentially modified sermorelin with similar duration.

How Does It Work?

Like other GHRH analogs, CJC-1295 stimulates the pituitary gland to release growth hormone. The modification allows it to resist the enzyme DPP-IV that normally breaks down GHRH quickly.

The DAC version produces sustained GH elevation, while the non-DAC version produces more natural pulsatile release.

Research Status

What Studies Show

• Phase I/II trials showed significant GH and IGF-1 increases
• The DAC version raised IGF-1 levels for extended periods
• Some studies combined it with ghrelin mimetics
• Development was discontinued; reasons not publicly detailed

Evidence Level

Limited human data exists from early-phase trials. No completed Phase III trials. Long-term safety data is unavailable.

Important Warnings

• Neither version is approved for any use
• Available only from unregulated sources
• The DAC version may cause prolonged side effects
• Banned in competitive sports

---

This guide is for educational purposes only. CJC-1295 is not approved by any regulatory agency.